High materiality9/10
Relay Therapeutics initiated with a Buy at Canaccord
Why it may matterVerify against the original reporting
Strong upside from new Buy.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Canaccord Genuity initiates BUY on RLAY with a $29 target (current price $19.51).
- Canaccord initiates BUY on RLAY; target $29; price $19.51.
Key facts
- 01
Target: $29
- 02
Posted price: $19.51
- 03
Analyst firm: Canaccord Genuity
- 04
Analyst: John Newman
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.